Preeclampsia:: increased expression of soluble ADAM 12
Preeclampsia:: increased expression of soluble ADAM 12
复制标题
DOI：
10.1007/s00109-005-0714-9
复制
发表时间：
2005-11-01
影响因子：
4.7
通讯作者：
Schorpp-Kistner, M
中科院分区：
文献类型：
--
作者：
Gack, S;Marmé, A;Schorpp-Kistner, M
先兆子痫是一种多系统妊娠相关疾病，影响全球约3-7%的妊娠，并且仍然是胎儿和孕产妇发病和死亡的主要原因。为了确定潜在的标志物，我们比较了基因表达谱从控制和先兆子痫胎盘组织采取在不同的年龄匹配的妊娠阶段，使用互补的DNA微阵列分析。除了先前确定的先兆子痫相关基因，新的差异表达的转录本被发现。可溶性形式的解整合素金属蛋白酶ADAM 12（解整合素和金属蛋白酶12; meltrin-alpha）代表最上调的转录本。这一点已通过先兆子痫胎盘切片的原位杂交和先兆子痫孕妇血清蛋白分析得到证实。因此，ADAM 12可以作为先兆子痫的早期生物标志物，可能具有预测和/或功能意义。
Preeclampsia is a multisystemic pregnancy-associated disease affecting about 3-7% of pregnancies worldwide and is still a principal cause of fetal and maternal morbidity and mortality. To identify potential markers, we have compared gene expression profiles from control and preeclamptic placental tissues taken at various age-matched gestational stages using complementary DNA microarray analysis. Besides previously identified preeclampsia-associated genes, novel differentially expressed transcripts were found. The soluble form of the disintegrin metalloprotease ADAM 12 (a disintegrin and metalloproteinase 12; meltrin-alpha) represented the most upregulated transcript. This was confirmed by in situ hybridization of sections of preeclamptic placentas and by serum protein analysis of preeclamptic pregnant women. Thus, ADAM 12 could serve as an early biomarker for preeclampsia that may be of predictive and/or functional significance.